Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

QUT researchers get new insight into ovarian cancer

Queensland scientists have made significant inroads into our understanding of the deadliest form of ovarian cancer after identifying two enzymes that make it resistant to chemotherapy.

29 Jan 2014

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Moderate radiation doses can kill premalignant cells and prevent second breast cancers

Survivors of breast cancer have a one in six chance of developing breast cancer in the other breast. But a study conducted in mice suggests that survivors can dramatically reduce that risk through treatment with moderate doses of radiation to the unaffected breast at the same time that they receive radiation therapy to their affected breast.

24 Jan 2014

Rival proteins’ relative expression levels in cancer cells could be biomarkers for prognosis, treatment

Consider two drivers, each with a key that fits the same car. Driver 1 wants simply to turn on the ignition and leave the vehicle idling, ready and waiting to roll. Driver 2 wants to take it on a destructive joy ride.

24 Jan 2014

USF Health and FORCE receive award from PCORI to develop and expand health data network

A team led by the University of South Florida (USF Health) Morsani College of Medicine and the leading national hereditary breast and ovarian cancer advocacy organization, FORCE (Facing Our Risk of Cancer Empowered), has received a $960,026 award from the Patient-Centered Outcomes Research Institute (PCORI) to develop and expand a health data network that will be part of PCORnet: the National Patient-Centered National Clinical Research Network.

24 Jan 2014

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel.

23 Jan 2014

Researchers find that 20% of women with ovarian cancer had inherited mutations in gene pathway

A new study conservatively estimates that one in five women with ovarian cancer has inherited genetic mutations that increase the risk of the disease, according to research at Washington University School of Medicine in St. Louis.

23 Jan 2014

Girls treated for Hodgkin's disease during adolescence acquire risk of developing breast cancer

Girls treated for Hodgkin's disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an observational study published in the current issue of Deutsches Ärzteblatt International.

22 Jan 2014

Genetic counseling delivered over telephone as effective as face-to-face counseling, says study

Genetic counseling delivered over the telephone is as effective as face-to-face counseling, finds the largest randomized study to date comparing the two methods. The multi-center study, led by researchers at Georgetown Lombardi Comprehensive Cancer Center, was reported today in the Journal of Clinical Oncology.

22 Jan 2014

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

Researchers at Case Western Reserve University have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer - a breakthrough that has the potential to improve outcomes for patients with the disease.

9 Jan 2014

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

Two research powerhouses, Loyola University Chicago and the University of Notre Dame, are joining forces in a multidisciplinary cancer research collaboration.

8 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.

31 Dec 2013

Alliance for Cancer Gene Therapy grants nearly $25M to conduct cancer related gene therapy research

As the potential of gene and cell therapy in fighting cancers grows and oncologists across the nation explore the burgeoning science, doctors have uncovered a stunning development – cancers can be treated using patients' own cells as a weapon, and can eliminate the harrowing, often debilitating effects of chemotherapy, radiation and surgery.

28 Dec 2013

Researchers discover cancer-killing properties of frankincense in ovarian cancer

Researchers from the University of Leicester have, for the first time, demonstrated the potential of treating ovarian cancer using the Christmas gift frankincense.

20 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Scientists back ovarian cancer preventative surgery to improve survival

A study by Manchester scientists backs preventative surgery to improve survival for women who are at greater risk of getting ovarian cancer and suggests it appears helpful for women at risk of getting breast cancer because of genetic faults.

18 Dec 2013

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

13 Dec 2013

More outreach needed for family members who carry genetic risks of cancer

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves-despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

13 Dec 2013

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

QUT researchers get new insight into ovarian cancer

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Moderate radiation doses can kill premalignant cells and prevent second breast cancers

Rival proteins’ relative expression levels in cancer cells could be biomarkers for prognosis, treatment

USF Health and FORCE receive award from PCORI to develop and expand health data network

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Researchers find that 20% of women with ovarian cancer had inherited mutations in gene pathway

Girls treated for Hodgkin's disease during adolescence acquire risk of developing breast cancer

Genetic counseling delivered over telephone as effective as face-to-face counseling, says study

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Alliance for Cancer Gene Therapy grants nearly $25M to conduct cancer related gene therapy research

Researchers discover cancer-killing properties of frankincense in ovarian cancer

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Scientists back ovarian cancer preventative surgery to improve survival

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

More outreach needed for family members who carry genetic risks of cancer

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in